COVID-19 is more severe in patients with hypertension; ACEI/ARB treatment does not influence clinical severity and outcome

J Infect. 2020 Dec;81(6):979-997. doi: 10.1016/j.jinf.2020.05.056. Epub 2020 May 28.
No abstract available

Keywords: Angiotensin receptor blocker (ARB); Angiotensin-converting enzyme inhibitor (ACEI); Coronavirus disease 2019 (COVID-19); Hypertention; Outcome; Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Angiotensin Receptor Antagonists / adverse effects
  • Angiotensin Receptor Antagonists / therapeutic use*
  • Angiotensin-Converting Enzyme Inhibitors / adverse effects
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
  • COVID-19 / epidemiology*
  • COVID-19 Drug Treatment
  • China
  • Female
  • Humans
  • Hypertension / drug therapy*
  • Hypertension / epidemiology
  • Male
  • Middle Aged
  • SARS-CoV-2
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors